In murine models for B-cell lymphomas [144] and colon adenocarcinoma [145], treatment with a MV vaccine strain displaying an insertion of the granulocyte-macrophage colony-stimulating factor (GM-CSF) resulted in a retarded tumor progression and an increased median overall survival time [144,145]. The gene discussed is CSF2; the disease is colon adenocarcinoma.